See “What Are Side Effects Associated with Using Atezolizumab?” Long-Term Effects See “What Are Side Effects Associated with Using Atezolizumab?” Cautions Immune-mediated pneumonitis orinterstitiallung disease occurred; monitor for signs and symptoms of pneumonitis; incidence of pneumonitis is higher ...
DRUG side effectsATEZOLIZUMABLUNG cancerCANCER patientsDRUG monitoringAtezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3...
TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] ...
Small-cell lung cancer (SCLC) Hepatocellular carcinoma (HCC) Melanoma Alveolar soft part sarcoma (ASPS) Tecentriq may also be used for other conditions as determined by your healthcare provider. How does Tecentriq work (mechanism of action)? Tecentriq is a type of medicine known as immunotherapy...
The potential impact of concomitant medications such as systemic antibiotics, proton pump inhibitors (PPIs), and probiotics in patients with extensive‐stage small cell lung cancer (ES‐SCLC) receiving first‐line chemo‐immunotherapy combinations remains unclear. We ran a post hoc analysis of the IMp...
Learn about the signs & symptoms of small cell lung cancer (SCLC), also known as oat cell carcinoma. See full safety for more information.
6. Johnson BE: Divide and conquer to treat lung cancer.N Engl J Med 375:1892-1893, 2016. Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer In the phase III OAK trialreported inThe Lancetby...
Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Liver cancer (HCC), & Adva
Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizu...
Atezolizumab is an immune checkpoint inhibitor that is a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury. Several patterns of liver injury associated with immune checkpoint inhibitor therapy have been reported; however, not...